
TTOO
USDT2 Biosystems Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$0.155
高値
$0.155
安値
$0.142
出来高
0.04M
企業ファンダメンタルズ
時価総額
4.0M
業種
Diagnostics & Research
国
United States
取引統計
平均出来高
0.09M
取引所
PNK
通貨
USD
52週レンジ
AI分析レポート
最終更新: 2025年5月26日TTOO: T2 Biosystems Inc. Common Stock – Unpacking Recent Trends and Future Possibilities
Stock Symbol: TTOO Generate Date: 2025-05-26 23:01:09
Let's break down what's been happening with T2 Biosystems and what the numbers might be telling us.
The Latest Vibe: What's the Word on the Street?
There's no specific news content provided here, so we can't gauge the immediate public sentiment from recent headlines. However, the AI's recommendation data gives us a peek into the underlying technical and fundamental health of the company. It's leaning quite positive, pointing to "Bullish Momentum" and even calling TTOO an "Undervalued Gem." That's a strong signal, suggesting the overall feeling, at least from a data-driven perspective, is optimistic.
Why the positive spin? The AI highlights a few key things:
- Technical Strength: The stock price is currently above its 20-day moving average, which is often a good sign for short-term momentum. Plus, indicators like the DMI and MACD are flashing "buy" signals, suggesting the stock's upward trend might be gaining steam.
- Value Potential: The company's P/E ratio is significantly lower than its industry average. This could mean the stock is undervalued compared to its peers, offering a potential bargain.
- Growth on the Horizon: Revenue growth at nearly 35% is certainly above average, indicating the company is expanding its business.
So, while we don't have news headlines, the analytical tools are painting a picture of a company with some solid underlying strengths and positive momentum.
Price Check: What Has TTOO Been Doing Lately?
Looking at the past few months, TTOO's price action has been a bit of a rollercoaster, but with a recent upward tilt. Back in late February, it was trading around $0.10-$0.16. Through March and April, the price mostly hovered in the $0.10-$0.12 range, showing some stability but not much excitement. Volume was generally low during this period, indicating less trading activity.
Then, something shifted in early May. We saw a noticeable jump, with the price moving from around $0.12 on May 1st to as high as $0.18 by May 6th. While it has pulled back slightly since then, settling around $0.15-$0.16 in mid-May, the overall trend from early May has been more positive than the preceding months. The stock closed at $0.16 on May 23rd.
Comparing this to the AI's insights, the current price of $0.16 is indeed above the 20-day moving average of $0.15, which aligns with the "Bullish Momentum" tag. The recent price action confirms this upward push we've seen.
Putting It All Together: What's the Outlook and What Could You Do?
Given the AI's strong bullish signals – the technical indicators, the perceived undervaluation, and the revenue growth – combined with the recent upward movement in the stock price, the near-term leaning for TTOO appears to favor potential buyers. It seems the market, or at least the AI's analysis, sees room for this stock to climb.
Potential Entry Consideration: If you're thinking about TTOO, the AI suggests potential entry points around $0.15 to $0.16. This makes sense, as $0.15 is the current 20-day moving average, often a level where a stock finds support during an uptrend. Entering around the current price of $0.16 could be considered, especially if the bullish momentum continues.
Potential Exit/Stop-Loss Consideration: Managing risk is always key. The AI provides a stop-loss level at $0.1425. This means if the stock drops below this point, it might be a signal to cut losses, as the bullish trend could be breaking down. On the flip side, for taking profits, the AI suggests a target of $0.21. This would represent a decent gain from current levels and aligns with the idea of a "bullish breakout."
Company Context: A Quick Look at T2 Biosystems
T2 Biosystems is in the diagnostics and research space within healthcare. They develop and sell diagnostic products, particularly for detecting pathogens and infections like sepsis and candidemia. They also have products in development for conditions like Lyme disease. With 113 full-time employees, it's a relatively small company.
It's important to remember that this is a small-cap stock (Market Cap: $4.5 million) with relatively low trading volume (Average Volume: 109,818). This means it can be quite volatile, and prices can swing significantly on relatively small amounts of trading. The AI also flags "Extreme Volatility" and "Low Trading Volume" as risk factors, which is crucial to keep in mind. While the P/E ratio is negative, which is common for growth-focused biotech companies, the AI sees it as undervalued compared to its industry peers.
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks carries inherent risks, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial professional before making any investment decisions.
AI予測Beta
AI推奨
更新日時: 2025年6月12日 12:48
56.5% 信頼度
リスクと取引
エントリーポイント
$0.14
利確
$0.17
損切り
$0.13
主要因子
関連株式

CGBDL
Carlyle Secured Lending Inc. 8.20% Notes due 2028

PHAR
Pharming Group N.V. ADS each representing 10 ordinary shares

MBINN
Merchants Bancorp Depositary Shares Preferred Series C

SBFG
SB Financial Group Inc.

OLED
Universal Display Corporation
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。